• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:04:31 PM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OBSV alert in real time by email
    SC 13G/A 1 ss192042_sc13ga.htm AMENDMENT NO. 2

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     (Amendment No. 2)*



     

    ObsEva SA
    (Name of Issuer)

     

     

    Common Stock
    (Title of Class of Securities)

     

     

    H5861P103
    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

       

     

      

    CUSIP No. H5861P103  SCHEDULE 13G Page 2 of 8 Pages

     

             
    1

    NAME OF REPORTING PERSONS

     

    OrbiMed Capital GP V LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.00%

    12

    TYPE OF REPORTING PERSON

     

    OO

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 3 of 8 Pages

     

             
    1

    NAME OF REPORTING PERSONS

     

    OrbiMed Advisors LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

       

     

      

    CUSIP No.  H5861P103  SCHEDULE 13G Page 4 of 8 Pages

     

    Item 1.   (a) Name of Issuer:

    ObsEva SA

        (b) Address of Issuer’s Principal Executive Offices:

    Chemin des Aulx, 12

    1228 Plan-les-Ouates

    Geneva, Switzerland

    Item 2.   (a) Name of Person Filing:

    OrbiMed Capital GP V LLC

    OrbiMed Advisors LLC

        (b) Address of Principal Business Office:

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

        (c) Citizenship:

    Please refer to Item 4 on each cover page for each Reporting Person.

        (d) Title of Class of Securities:

    Common Stock, Par Value $0.0001 Per Share

        (e) CUSIP No.:

    H5861P103

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 5 of 8 Pages

     

     

    Item 3.      

    OrbiMed Capital GP V LLC (“GP V”) is the general partner of OrbiMed Private Investments V, LP. OrbiMed Advisors LLC (“Advisors”) is an investment advisor in accordance with ss.240.13d-1(b)(1)(ii)(E) and Advisors is the managing member of GP V.

     

     

     

     

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 6 of 8 Pages

     

     

    Item 4. Ownership:

    Information with respect to the Reporting Person’s ownership as of December 31, 2020 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

       

     

     

    CUSIP No. H5861P103  SCHEDULE 13G Page 7 of 8 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021

     

     

      OrbiMed Advisors LLC
           
      By: /s/ Jonathan T. Silverstein  
        Name:  Jonathan T. Silverstein
        Title:  Member
           
      By: /s/ Sven H. Borho  
        Name:  Sven H. Borho
        Title:  Member
           
      By: /s/ Carl L. Gordon  
        Name:  Carl L. Gordon
        Title:  Member
           
           
     

    OrbiMed Capital GP V LLC

    By: OrbiMed Advisors LLC, its Managing Member

           
      By: /s/ Jonathan T. Silverstein  
        Name:  Jonathan T. Silverstein
        Title:  Member of OrbiMed Advisors LLC
           
      By: /s/ Sven H. Borho  
        Name:  Sven H. Borho
        Title:  Member of OrbiMed Advisors LLC
           
      By: /s/ Carl L. Gordon  
        Name:  Carl L. Gordon
        Title:  Member of OrbiMed Advisors LLC
           
             

     

     

     

    Get the next $OBSV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OBSV

    DatePrice TargetRatingAnalyst
    8/30/2022Buy → Neutral
    H.C. Wainwright
    6/3/2022$6.00Overweight
    Cantor Fitzgerald
    4/26/2022$12.00Buy
    Canaccord Genuity
    3/28/2022$12.00Buy
    Aegis Capital
    11/29/2021$17.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OBSV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Loumaye Ernest

      4 - ObsEva SA (0001685316) (Issuer)

      4/11/23 4:02:23 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Loumaye Ernest bought $440,000 worth of shares (4,000,000 units at $0.11), increasing direct ownership by 200% to 6,000,000 units

      4 - ObsEva SA (0001685316) (Issuer)

      3/2/23 4:16:42 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brown William Michael

      4 - ObsEva SA (0001685316) (Issuer)

      2/24/23 4:50:38 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care